Medicaid payment policies for methadone maintenance treatment for opioid use disorder, 2020-2025 Authors: Yuhua Bao, Promi Chakraborty, Kayla Hutchings, Shashi N Kapadia, Noa Krawczyk, Bruce R Schackman, Barbara Andraka-Christou, Ju-Chen Hu Published: 2026 ABSTRACT AbstractBackgroundThe potential of methadone maintenance treatment (MMT) to address the opioid crisis has been limited by restrictive federal and local policies that require frequent clinic visits for medication. Unprecedented federal regulatory changes started in early COVID-19 and were made permanent in 2024, allowing clinics increased flexibility in granting take-home medication to patients. Medicaid payment policies can profoundly shape provider behaviors but may not align with regulatory changes.MethodsWe conducted a systematic synthesis of Medicaid MMT payment and billing policies among 40 states over March 2020-July 2025.ResultsMore than half of the states continued to adopt a per-dose or per-diem approach to paying for methadone dosing and a per-service approach to paying for addiction counseling, thus tying Medicaid revenue closely to clinic visits. More than one-quarter maintained a flat bundled payment dating back to prepandemic era that provided little incentive for granting patients more than 1 week of take-home medication. Adoption of a 2-tiered bundled payment modeled after Medicare's payment increased over time but remained limited.ConclusionMedicaid payment policies for MMT saw limited changes over the 5 years following initial federal regulatory changes. Practice changes toward more flexible and patient-centered care may be hindered without compatible changes in payment approaches. Introduction Methadone is the oldest of 3 medications approved by the Food and Drug Administration for opioid use disorder (OUD). Despite increasing evidence that supports methadone as the medication of choice compared to buprenorphine when addressing fentanyl-related OUD,1,2 access to this medication is limited. A myriad of federal and state statutes and regulations limit its administration and dispensing to federally certified opioid treatment programs (OTPs) and, prior to 2020, had required frequent clinic visits to receive observed dosing of the medication.3 Such regulations and practices created heavy burdens referred to by patients as “liquid handcuffs”4 and severely limited access to and retention in MMT. The COVID-19 pandemic ushered in substantial relaxation of federal regulations for OTPs. A signature change allowed for greater flexibility in granting patients take-home doses of methadone. This flexibility was first provided in pandemic-era blanket exceptions5 and then made permanent in the 2024 Substance Abuse and Mental Health Services Agency (SAMHSA)'s final rule for OTPs, allowing for weeklong take-home doses as early as the first 2 weeks of MMT and more doses (up to 28 days) as time in treatment increases.6 The final rule also relaxed other historical requirements, such as no longer requiring addiction counseling as a condition for medication. Existing data, however, suggest average low7-9 but varied7,10-12 adoption of take-home dosing by OTPs in the early years of the pandemic and a gradual return to more restrictive practices once the risk of COVID-19 dissipated.13 Data reflecting OTP practices after the SAMHSA final rule are limited. There is no evidence that expanded take-home dosing has been realized on a large scale. Restrictive financing mechanisms or misaligned financial incentives could be a major barrier to sustained take-home practice changes at OTPs.14 State Medicaid payment policies may be of particular importance, given that >60% of adults receiving treatment for OUD in 2024 were covered by Medicaid.15 Prior to the COVID-19 pandemic, many state Medicaid programs paid for methadone administration and related services (eg, addiction counseling) on a per-service or per-diem basis, tying payment closely to onsite medication administration.16 Those payment models could be misaligned with more flexible take-home dosing if the per-dose or per-diem payment were for onsite dosing only and did not cover take-home dosing. Moreover, when patients were not visiting the clinic as often, OTPs would have a harder time engaging patients in other revenue-generating services like counseling, which, in itself, disincentivizes take-home dosing. The fact that the final rule no longer requires counseling for patients receiving MMT further added to the revenue concern related to lower counseling frequency.17 Meanwhile, Medicare started covering MMT in January 2020 and implemented a 2-tiered, weekly bundled payment.18 The higher tier represents a full bundle for a week in which one or more “qualifying services” (eg, onsite dosing, individual or group counseling) are provided. The lower tier has a much lower payment rate for a week in which patients are maintained on take-home doses and no other qualifying services are provided, known as a “medication-only week.” An unknown number of Medicaid programs adopted Medicare's model during the pandemic to mitigate the “revenue shock” to OTPs associated with reduced onsite dosing.19 While the bundled payment breaks the close tie between onsite dosing (and related services such as counseling) and payment, the stark difference in the bundled rates between the 2 tiers provides strong incentives to restrict take-home dosing to a weekly schedule rather than longer (eg, 2-week) schedules.17 Medicaid payment policies for MMT may have further evolved in recent years, given the changing policy landscape but may also present substantial heterogeneity across states that reflect different trajectories in state policy priorities. We sought to systematically synthesize Medicaid payment policies and how they evolved over the 5 years following the start of the COVID pandemic. We based our synthesis on a review of official state policy documents, reflecting policies for traditional Medicaid. To our knowledge, Medicaid managed care plans, to a large extent, carve out MMT benefits to behavioral health specialty plans or traditional Medicaid,20 suggesting that our findings may apply to a large proportion of managed care enrollees as well. Methods Scope of policy synthesis We initially included 43 Medicaid programs (“states” hereafter) that started covering MMT before March 1, 202021 and were thus exposed to federal regulatory changes for OTPs since the early phase of COVID-19. As detailed below, 40 of the 43 states had available data and were included in the synthesis. This study did not require review by an Institutional Review Board because no human subjects were involved. In December 2022, SAMHSA issued proposed rules20 indicating its intention to make many of the COVID-related flexibilities permanent, a significant move that could have prompted states to align their Medicaid payment policies with anticipated permanent federal rule changes. We thus synthesized policies over 2 periods: March 2020-December 2022 and January 2023-July 2025. Data Policy documents were collected from 2 major sources: the Nexis Uni® database and Google-assisted internet searches. Nexis Uni is a database of news, legal, and business sources from Lexis Nexis, specifically curated for academic research. Our team of 2 behavioral health policy experts, 1 legal expert, and 2 research assistants iteratively developed search strings (Appendix A) that included multiple relevant terms for MMT, methadone take-home practices, and billing/payment. Two researchers independently searched the “Statutes and Legislations,” “Administrative Codes and Regulations,” and “Administrative and Agency Codes” sections of Nexis Uni by state, reviewed each document to determine relevancy, and met regularly to reconcile discrepancy in identified documents. Upon achieving very high agreements in identified documents after the first 18 states, the 2 researchers split search tasks for the rest of the states. Medicaid payment and billing policies typically do not exist in the form of legislation or coded regulations. Rather, they exist in provider manuals, billing guidance, fee schedules, and communications (eg, state agency announcements, provider bulletins, letters to providers). We thus conducted systematic and extensive web searches for these documents. Since Google searches do not support complex Boolean search strings, we adopted the following approach. We started with a Google search with keywords: “State Name” + “methadone” + “Medicaid” + “billing.” Once we identified relevant documents based on this initial search, we then refined the keywords used for the index state and updated the search. When initial searches identified a type of documents that was likely published/issued regularly (eg, fee schedules), we adopted a snowballing approach by specifically looking for the same type of documents from years before and after the identified document. For webpages that have yielded relevant documents, we used the Wayback Machine internet archive21 for documents that could have been archived. Google AI overviews were not examined. The same 2 researchers collaborated on the Google-assisted searches by following a similar protocol as in the Nexis Uni searches. Document extraction included a process to determine the date on which policies took effect. Although a majority (63%) of the documents carried an “effective date,” many did not. Some documents contained other date-related information (eg, “updated date” or “publication date”) or multiple types of dates. We developed hierarchical rules to assign a date and iteratively refined the rules as the team deepened knowledge regarding how policy documents were dated (Appendix B). Analysis Our analysis of identified documents included 4 steps: (1) coding texts from identified documents, (2) developing questions, largely binary, to characterize Medicaid payment and billing policies, (3) characterizing prevailing policies by answering questions for a given state at a given time, and (4) summarizing policies for each state and for the national landscape in each of the 2 study periods. We uploaded full documents into the qualitative research software Dedoose®. Given the purpose of this study and upon reviewing documents from 4-5 states, the team collectively developed 2 broad codes, “payment for methadone” and “take-home doses.” Two researchers read through all documents and conducted deductive coding independently by assigning labels to texts. They met regularly to discuss and reconcile discrepancies in coding and discuss nonresolved discrepancies with a larger team until a final code was assigned. We iteratively developed a set of cascading questions, operationalized as a decision table, to characterize salient aspects of Medicaid payment and billing policies for MMT, especially relating to compatibility with OTPs' needs to practice flexible take-home dosing. Appendix C provides the decision table framework, with rows pertaining to the questions and columns pertaining to Month-Years ranging from March 2020 to July 2025, with an additional column for “Pre 03/2020,” to be determined based on the most recent available documents prior to 03/2020. We first asked whether a Medicaid program covered MMT with a per-dose (ie, paying for methadone administration/dispensing on a dose-by-dose basis) or per-diem (ie, paying for MMT services with a daily rate that typically covers services in addition to dosing), vs a bundled payment (ie, a prospective payment covering a defined set of MMT services over a defined billing period) approach. Detailed definitions and examples are provided in Appendix D. If per-dose/per-diem, we further determined whether the payment covered take-home doses. For states that adopted a per-diem approach, we sought to determine if the daily rate covered addiction counseling. For bundled payments, prior knowledge and initial data analysis indicated 2 distinct designs: (1) a flat bundled rate and (2) a 2-tiered design modelled after Medicare's payment for MMT. The decision table sought to determine which bundled design a given Medicaid program had at a given time, and, regardless of the design, the types of “qualifying services” that were covered under the bundled payment. The 2 researchers who led document coding conducted initial determination for a small number of states and discussed preliminary determinations with 2 behavioral health policy experts in weekly meetings to resolve ambiguities, reach consensus, develop, update, and document decision rules and rationales (Appendix D). Month-Year-specific determinations were made strictly based on coded texts from document(s) indexed to a Month-Year. Columns without any indexed document were left blank. Once the initial round was completed, the research team developed and applied logic rules to “impute” certain cells that were “Not Known” based on the initial determination. To summarize key characteristics of MMT payment and billing policies for each state, we extracted the last known data point in Period 1 and in Period 2, reflecting a snapshot close to the end of each period. We then synthesized these data across states to describe how the national landscape evolved over time. Appendix E summarizes the multistep approach to collecting and analyzing policy data in this study. Results Our searches identified a total of 339 policy documents pertaining to the 43 states initially included in the study, with 1 identified from the Nexis-Uni database and 338 from Google-assisted internet searches. The Nexis-Uni search (using a search string) initially generated 471 documents; 470 of the 471 documents provided no information on payment policies for MMT. For Period 1 (03/2020-12/2022), the number of documents identified per state ranged from 1 to 12, with a median of 3. For Period 2 (01/2023-07/2025), it ranged from 1 to 13, with a median of 3. Overall, Medicaid fee schedules accounted for 36% of all documents, followed by provider manuals/billing guidance documents (31%) and state agency communications to providers (26%). A small number of documents (6%) did not fall into any of the categories or had an unknown document type (1%). We synthesized results below for 40 states with at least one informative document in each study period that allowed us to determine the overall payment approach: per-dose/per-diem vs a flat bundled payment vs the Medicare-style bundle (Table 1). South Dakota and Utah were excluded because we did not find any document in Period 1; Hawaii was excluded because documents from Period 2 did not provide sufficient information to support determination. Table 1.Summary of Medicaid payment and billing approaches for methadone maintenance treatment across the 40 states included in policy synthesis.StatePeriod 1: 03/2020 to 12/2022Period 2: from 01/2023 to 07/2025AlabamaPer-dose or per-diem paymentPer-dose or per-diem paymentAlaskaPer-dose or per-diem paymentPer-dose or per-diem paymentArizonaPer-dose or per-diem paymentPer-dose or per-diem paymentCaliforniaPer-dose or per-diem paymentPer-dose or per-diem paymentColoradoPer-dose or per-diem paymentPer-dose or per-diem paymentConnecticutPer-dose or per-diem paymentPer-dose or per-diem paymentDelawarePer-dose or per-diem paymentPer-dose or per-diem paymentDistrict of ColumbiaPer-dose or per-diem paymentPer-dose or per-diem paymentFloridaFlat weekly bundled paymentFlat weekly bundled paymentGeorgiaPer-dose or per-diem paymentPer-dose or per-diem paymentIllinoisFlat weekly bundled paymentFlat weekly bundled paymentIndianaPer-dose or per-diem paymentMedicare-style bundle paymentIowaMedicare-style bundle paymentMedicare-style bundle paymentKentuckyFlat weekly bundled paymentFlat weekly bundled paymentLouisianaPer-dose or per-diem paymentPer-dose or per-diem paymentMaineFlat weekly bundled paymentFlat weekly bundled paymentMarylandFlat weekly bundled paymentFlat weekly bundled paymentMassachusettsPer-dose or per-diem paymentPer-dose or per-diem paymentMichiganPer-dose or per-diem paymentPer-dose or per-diem paymentMinnesotaPer-dose or per-diem paymentPer-dose or per-diem paymentMississippiMedicare-style bundle paymentMedicare-style bundle paymentMissouriPer-dose or per-diem paymentPer-dose or per-diem paymentMontanaFlat weekly bundled paymentFlat weekly bundled paymentNevadaPer-dose or per-diem paymentPer-dose or per-diem paymentNew HampshirePer-dose or per-diem paymentMedicare-style bundle paymentNew JerseyFlat weekly bundled paymentMedicare-style bundle paymentNew MexicoPer-dose or per-diem paymentPer-dose or per-diem paymentNew YorkBoth per-dose and bundled paymentBoth per-dose and bundled paymentNorth CarolinaPer-dose or per-diem paymentFlat weekly bundled paymentOhioPer-dose or per-diem paymentPer-dose or per-diem paymentOregonPer-dose or per-diem paymentPer-dose or per-diem paymentPennsylvaniaPer-dose or per-diem paymentPer-dose or per-diem paymentRhode IslandFlat weekly bundled paymentFlat weekly bundled paymentSouth CarolinaFlat weekly bundled paymentFlat weekly bundled paymentTexasPer-dose or per-diem paymentPer-dose or per-diem paymentVermontFlat monthly bundled paymentFlat monthly bundled paymentVirginiaPer-dose or per-diem paymentPer-dose or per-diem paymentWashingtonFlat weekly bundled paymentFlat weekly bundled paymentWest VirginiaFlat weekly bundled paymentFlat weekly bundled paymentWisconsinPer-dose or per-diem paymentPer-dose or per-diem payment Summary of Medicaid payment and billing approaches for methadone maintenance treatment across the 40 states included in policy synthesis. In Period 1, out of the 40 states, 25 paid for MMT with a per-dose/per-diem approach, 14 states had a bundled approach, and 1 state (New York) adopted both as alternative payment approaches for any patient-week. In Period 2, 22 states paid for MMT with a per-dose/per-diem approach; 17 states had a bundled approach; New York remained the only state with both approaches (Figure 1). Number of states with a per-dose/per-diem vs a bundled payment for MMT among 40 states included in policy synthesis, March 2020-July 2025. Source: Authors' analysis of Medicaid payment and billing policy documents identified from the internet. Notes: Of the 43 states whose Medicaid programs covered MMT as of March 2020, 40 were included in policy synthesis because they had at least one informative document in each study period that allowed for the determination of the program's overall payment approach. In Period 1, of the 25 states paying for MMT with a per-dose/per-diem approach, 16 explicitly covered take-home doses (Appendix F). In Period 2, of the 22 states with a per-dose/per-diem approach, 12 explicitly covered take-home doses. We could not determine take-home coverage for the remaining states. New York's per-dose/per-diem approach (known as the Ambulatory Provider Group or APG payment) did not cover take-home doses. Of all states with a per-dose/per-diem approach, 7 out of 25 in Period 1 and 6 out of 22 in Period 2 had a per-diem rate that covered services in addition to dosing and toxicology testing. We could not determine the per-diem (vs per-dose) status for 3 states in Period 1 and 2 states in Period 2. Of states adopting a per-diem approach, 4 (out of 7) in Period 1 and 3 (out of 6) in Period 2 explicitly covered counseling in their daily rate. In both periods, California's daily rate did not cover counseling; we were not able to determine counseling coverage for Alabama or Georgia (Appendix G). Fifteen states in Period 1 and 14 in Period 2 (and New York) adopted a per-dose rate that did not cover additional services other than toxicology testing. Figure 2 breaks down the group of states adopting a bundled payment into those with a flat bundle and those with a Medicare-style, 2-tiered bundle. The number of states with a flat bundle remained at 12 in both periods. Except for Vermont, which had a monthly bundled rate throughout study years, all these states had a flat weekly rate. In both periods, 6 out of 12 states covered counseling as part of the bundle; 3 did not; for the other 3 states, identified documents were all fee schedules and did not allow us to determine coverage of counseling (Appendix H). We were not able to determine whether the flat bundle covered a “medication-only week” in either period except for Montana, where, to receive payment, OTPs were required to provide at least one “member check-in, at the clinic, the member's home, or via telemedicine” in a week,22,23 suggesting no payment for a medication-only week. Not counting New York (which adopted the Medicare-style bundle in both periods), states adopting the Medicare-style bundle increased from 2 in Period 1 to 5 in Period 2. We were able to find officially published rates of the 2 tiers for all 6 states with a Medicare-style bundle in Period 2 (including New York). The payment rate for the higher tier was 4-6 times as high as the rate for the medication-only tier. Number of states with a flat bundled payment vs a Medicare-style bundled payment for MMT among states using a bundled payment approach, March 2020-July 2025. Source: Authors' analysis of Medicaid payment and billing policy documents identified from the internet. Notes: States included in this summary included 14 states (+ New York) in Period 1 and 17 states (+ New York) in Period 2 that had a bundled payment for MMT. Overall, there were limited changes in Medicaid payment models for MMT from the early years of the pandemic to more recent years (Table 2). Three out of the 25 states with a per-dose/per-diem approach in Period 1 transitioned to a bundled approach: North Carolina transitioned to a flat weekly bundle and Indiana and New Hampshire to a Medicare-style bundle. Of the 12 states with a flat bundled payment in Period 1, only 1 (New Jersey) transitioned to the Medicare-style bundle in Period 2. For 10 out of the 12 states, identified documents from prior to March 2020 suggest that the flat bundled payment was already in place prior to the pandemic. For all 4 states that transitioned to a different payment model (Medicare-style or flat bundle) in Period 2, the transition happened prior to the release of the SAMHSA final rule in February 2024. Two states that adopted the Medicare-style bundle in Period 1 (Iowa and Mississippi) continued with that model in Period 2. New York State's dual-model approach was first adopted in March 2020 and remained throughout the study years. Table 2.Changes in payment models for MMT over the 2 study periods among 40 states included in policy synthesis.Period 2, January 2023-July 2025Per-dose/per-diemFlat weekly/monthly bundleMedicare-style, 2-tieredPer-dose and bundled as alternative payment Period 1, March 2020-December 2022 Per-dose/per-diem 22, no change120 Flat weekly/monthly bundle 011, no change10 Medicare-style, 2-tiered 002, no change0 Per-dose and bundled as alternative payment 0001, no changeSource: Authors' analysis of Medicaid payment and billing policy documents identified from the internet.Numbers in the table are counts of state Medicaid programs that experienced specified changes in payment models for MMT between the 2 study periods. Changes in payment models for MMT over the 2 study periods among 40 states included in policy synthesis. Source: Authors' analysis of Medicaid payment and billing policy documents identified from the internet. Numbers in the table are counts of state Medicaid programs that experienced specified changes in payment models for MMT between the 2 study periods. Discussion Our policy synthesis revealed that states made limited changes to how Medicaid programs paid for MMT from early COVID-19 years (2020-2022) to more recent years (2023-2025), during which time federal regulatory flexibilities for MMT were made permanent. More than half of the 40 states included in the synthesis continued to use a per-dose/per-diem approach by July 2025; more than one-quarter continued to use a flat weekly/monthly bundle that was largely unchanged from prior to the pandemic. Adoption of the Medicare-style, 2-tiered bundled payment increased over time but remained limited to 5 out of 40 states by July 2025. Five years after the start of the COVID-19 pandemic and 1 year following the SAMHSA final rule, the per-dose/per-diem approach still dominated the landscape of Medicaid payment and billing policies for MMT. Among states adopting a per-dose/per-diem approach, the per-dose approach dominated. Our synthesis showed that these approaches largely covered take-home doses as well as onsite doses, which helped limit revenue losses to OTPs as they pivoted to more take-home dosing during the pandemic. However, because billing for counseling remains separate in a per-dose approach and because increased take-home dosing likely implies less frequent counseling visits (and therefore less revenue from counseling), the incentives embedded in a per-dose (or per-service approach in general), despite the coverage of take-home doses, are misaligned with the goal of expanding take-home dosing. More than a quarter of the states included in the synthesis (11 out of 40) maintained a flat, largely weekly bundled payment throughout the study years. Our data indicates that, in all these states except 2 for which we lacked information, the same flat bundle was in effect prior to March 2020, when daily or almost daily onsite dosing was the norm. Counseling was not universally included in these flat bundles and was presumably billed separately. Incentives to maintain frequent clinic visits (and thus counseling revenue) were not mitigated. Since almost all flat bundles dated back to before COVID-19 and our data suggest little change in payment rules over time, they likely did not cover a “medication-only week” by the end of our study period. This feature strongly disincentivizes take-home dosing beyond 1 week. The Medicare-style bundle saw slow but increased adoption over the years by Medicaid programs. The 2-tiered design seeks to strike a balance between encouraging patient-centered care and matching payments to resource requirements. The stark difference in payment rates between the 2 tiers ($277.29 for a week with any “qualifying services” vs $44.41 for a medication-only week in the 2026 Medicare rates),24 however, provides OTPs a strong incentive to maintain at least weekly clinic visits and service engagement (esp., in counseling) that may or may not be aligned with patient-centered care.17 Medicaid programs adopting the Medicare-style bundle mostly followed this design feature, although the Medicaid rate for the higher tier was in general much lower than the Medicare rate, while the rate for a medication-only week was similar. An important reason underlying the sluggish adoption of the Medicare-style bundle could be the administrative and technical burdens associated with the transition. Such a transition may substantially complicate OTPs' billing protocols and workflow because OTPs need to determine, for each patient-week, whether to bill the higher tier or the medication-only tier. In addition, since the 2-tiered bundle may not cover all MMT-related services (for example, peer support services), OTPs would need to operate 2 different systems for billing. MMT practice changes toward more flexible and patient-centered care may be hindered without compatible changes in Medicaid payment and billing policies. Our policy synthesis found no major changes in Medicaid payment models during the 17 months following the release of the SAMHSA final rule. It is important to note that Medicaid payment policies are not the only policy changes required to support OTP practice changes. In many states, state regulations governing the delivery of MMT were historically highly restrictive25,26 and, if unchanged, may work against changes that federal regulations or Medicaid payment policies are meant to bring about. For example, although the federal final rule no longer requires counseling as a condition for medication, some states maintained strict requirements for minimum hours of counseling. In those states, even if Medicaid payment had transitioned to a Medicare-style bundle to be aligned with flexible take-home dosing, OTPs might have to maintain a high level of onsite dosing to meet the state counseling requirements. Implementation of the federal final rule thus calls for a concerted effort across multiple state regulatory units and comprehensive reviews of existing and new rules. By conducting original searches of policy documents on the internet, our approach was novel but subject to limitations. Documents identified were likely incomplete, and such incompleteness may vary across states in ways we cannot assess. Verification of collected data with state agencies and engagement of provider organizations and state administrators in developing search protocols and interpreting data, however, was beyond the scope of this study. The proliferation of Medicaid managed care (covering 66%-86% of non-elderly adult enrollees in 2023 nation-wide, depending on eligibility group)27 and varying structures of how MMT benefits were managed across states may compromise the generalizability of our findings. Nevertheless, it is likely that our findings may extend to Medicaid managed care plans in many states. For example, a previous study of Medicaid managed care plan arrangements for substance use disorder treatment in 10 states found that, for 95% of all plans, benefits for MMT were either managed by traditional Medicaid or carved out to a specialty behavioral health plan,20 which (in our experience) tend to adopt the same payment approach for MMT as specified in the state's official rules. Future work should explore the extent to which our study findings extend to Medicaid managed care. Conclusion Medicaid payment and billing policies for MMT experienced limited changes over the 5 years following the start of COVID-19. Per-dose/per-diem approaches and flat bundled rates continued to dominate the Medicaid payment landscape, potentially hindering expanded take-home dosing and related practice changes. Our findings highlight the importance of concerted and compatible state policy changes to support service transformation in MMT made possible by federal regulatory changes. Supplementary Material